Skip to main content

Day: January 31, 2024

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program. Seat16 allows anyone to gift $16 or more to purchase an ORIGIN movie ticket for a young person who might not otherwise be able to purchase a ticket to the film. For 23 days, 23andMe will donate 100 seats daily to support the program. ARRAY, the multi-platform arts and social impact collective founded by Ava DuVernay, created the Seat16 initiative to ensure that 10,000 young people across the nation get to experience ORIGIN. Written, directed, and produced by...

Continue reading

Check Point Software Unveils Infinity AI Copilot: Transforming Cyber security with Intelligent GenAI Automation and Support

Check Point’s latest innovation, brings AI-powered efficiency and collaboration to cyber security management across platforms BANGKOK, Thailand, Jan. 30, 2024 (GLOBE NEWSWIRE) — Check Point Software Technologies Ltd. (NASDAQ: CHKP), a leading AI-powered, cloud-delivered cyber security platform provider, today announced the launch of the first-generation Infinity AI Copilot. Leveraging the convergence of AI and cloud technologies, Infinity AI Copilot addresses the growing global shortage of cyber security practitioners by boosting the efficiency and effectiveness of security teams. “With Infinity AI Copilot, we are ushering in a new era of cyber security where human-machine collaboration takes center stage,” said Eyal Manor, VP of Product Management at Check Point Software Technologies. “Our vision is to enable security...

Continue reading

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

         NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: “It has been a very busy quarter in which we have made substantial operational progress across our three lead Phase 3 assets. We have generated significant new potency and characterization data for our lead product Ryoncil® (remestemcel-L) for children with acute GVHD, as requested by FDA, and will submit these data ahead of our planned meeting with FDA this quarter.” “Our second Phase 3 back pain trial with rexlemestrocel-L, aiming to confirm the durable pain reduction that was seen in the first Phase 3 trial, is underway. Finally, we were...

Continue reading

Regenx Revises Non-Brokered Financing for Gross Proceeds to $1.7 Million

EDMONTON, Alberta, Jan. 30, 2024 (GLOBE NEWSWIRE) — Regenx Tech Corp. (the “Company” or “Regenx”) (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS WKN:A2DSW3) announces that it has revised the previously announced unsecured and non-brokered Convertible Debenture Financing (“Offering”) for gross proceeds of $1,700,401.73. The Debentures will bear interest at the rate of fifteen percent (15%) per annum, payable on the maturity date and will mature on December 31, 2025. The Debentures will be convertible at the holder’s option into common shares of the Corporation (“Common Shares”) at a conversion price of: (i) $0.05 per Common Share until the date that is one (1) year from the closing date; and (ii) $0.105 per Common Share for the period from the date following one (1) year from the closing date until the maturity date....

Continue reading

Osino Announces Receipt of Interim Order and Closing of Second and Final Tranche of Bridge Private Placement

VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) — Osino Resources Corp. (TSXV:OSI) (NSX:OSN) (FSE:RSR1) (OTCQX:OSIIF) (“Osino” or the “Company“) is pleased to announce that the Supreme Court of British Columbia (the “Court”) has issued an interim order (the “Interim Order”) in connection with the previously announced plan of arrangement (the “Plan of Arrangement”) under the Business Corporations Act (British Columbia), pursuant to which Dundee Precious Metals Inc. (“DPM”) will acquire all of the issued and outstanding common shares of Osino (the “Arrangement”). For further information on the Arrangement and the definitive arrangement agreement between Osino and DPM (the “Arrangement Agreement”), please refer to the joint news release of the parties dated December 18, 2023. Interim Order The Interim...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.